Abstract Library

#1916 Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT

Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Singh A, Severi S, Drozdov I,

Keywords: PRRT, efficacy,

#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs

Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Kidd M, Tesselaar M, Korse T, Verbeek W, Drozdov I,

Keywords: Nomogram, prognosis, NETest, PFS, grade, biomarker,

#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs

Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Kidd M, Bodei L, Severi S, Drozdov I, Nicolini S,

Keywords: PRRT, nomogram, NETest, biomarker, OS, PFS, prediction,

#1569 Blood Measurement of NET Transcripts (NETest) Predicts Well-Differentiated Gastroenteropancreatic NET Disease Status and Is Prognostic for Disease Progression

Introduction: A key issue in GEP-NETs is early identification and prediction of disease progression. Clinical evaluation and imaging are limited due to the lack of sensitivity and disease indolence.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kidd M

Authors: Pavel M, Jann H, Prasad V, Drozdov I, Modlin I,

Keywords: PCR,

#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,

Keywords: NETest, PRRT,